Seres Therapeutics (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a "positive impact on biomarkers of systemic inflammation and immune homeostasis" compared with placebo.
The results back previous data showing that SER-155 "was associated with a significant reduction in bloodstream infections," the company said Thursday in a statement.
SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.
The company also said its cash runway was extended into Q1 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.